¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022³â ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ ÃæûÁöȸ 12¿ù Áý´ãȸ : 2022-12-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022³â ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ ÃæûÁöȸ 12¿ù Áý´ãȸ : 2022-12-20
±³À°ÀÏÀÚ : 2022-12-20
±³À°Àå¼Ò : ¹ÙÀÌ¿À´Ï¾Æ ±Û·Î¹ú¼¾ÅÍ ´ëÀü±¤¿ª½Ã À¯¼º±¸ °üÆòµ¿ 686  
±³À°ÁÖÁ¦ : 2022³â ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ ÃæûÁöȸ 12¿ù Áý´ãȸ
ÁÖÃÖ±â°ü : ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ÃæûÁöȸ  
´ã´çÀÚ : ÀÌÀ¯Áø
¿¬¶ôó : 070-4436-3304  
À̸ÞÀÏ : kscp2@kams.or.kr      
±³À°Á¾·ù : Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 30¸í
Èñ¸ÁÆòÁ¡ : 2Á¡  
Áö¿ª : ´ëÀü±¤¿ª½Ã
±³À°½Ã°£ : 2 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 0¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-20 PART1 16:10~16:25 Clinical Laboratory Innovations During COVID-19 Pandemic  Marrisa Orillaza(Department of Laboratory Medicine ACE Group of Hospitals) 
±³À°½Ã°£ 12-20 PART1 16:25~16:40 Latest Situation of COVID-19 in Hong Kong  Daniel Tam(CryolifeCompany Ltd) 
±³À°½Ã°£ 12-20 PART1 16:40~16:55 Pandemic Preparedness and Response: A Singapore Experience  Eddie Ang(Singapore Association for Medical Laboratory Sciences) 
±³À°½Ã°£ 12-20 PART1 16:55~17:10 Laboratory Response for COVID-19 in Korea  È«±âÈ£(¿¬¼¼ÀÇ´ë ¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 12-20 PART1 17:10~17:25 The Impact of COVID on the Blood Safety Program  Dorothy K. Byabazaire(Uganda Blood Transfusion Service Kampala) 
±³À°½Ã°£ 12-20 PART1 17:25~17:40 Analyse the Factors Affecting the Decision of EQA Sample Selection  Thai My Tran(Center for Standardization and Quality control in medical laboratory of HCMC, University of Economics Ho Chi Minh City) 
±³À°½Ã°£ 12-20 PART2 18:15~18:30 Challenges of Blood Donor Screening in Korea  ±èÇö¿Á(¿¬¼¼ÀÇ´ë ¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 12-20 PART2 18:30~18:45 HIV, HBV, HCV Quantitative Measurement and Clinical Application  ¹ÚÈñ¼ö(ÃæºÏ´ëÇб³º´¿ø) 
±³À°½Ã°£ 12-20 PART2 18:45~19:00 Advances in Antiviral Therapy and Viral Load Monitoring  ÀÌÇѾÆ(ÀÌ´ë¸ñµ¿º´¿ø) 
±³À°½Ã°£ 12-20 PART2 19:00~19:15 Laboratory Operations for Viral Load Testing and Surveillance  ¾çÁ¤¼®(°í´ë±¸·Îº´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022³â ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ ÃæûÁöȸ 12¿ù Áý´ãȸ : 2022-12-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) ´ëÇÑÁ¤Çü¿Ü°ú ºÎ»ê․¿ï»ê․°æ³²Áöȸ Á¦351Â÷ ¿Â¶óÀÎ ¿ù·ÊÇмúȸ : 2022-12-20
´ÙÀ½±Û (¿Â¶óÀÎ)2022 ´ëÇÑÀÀ±ÞÀÇ·áÁöµµÀÇ»çÇùÀÇȸ ÁöµµÀÇ»ç µ¿°è ¿¬¼ö°­Á : 2022-12-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20805 ¼­¿ï 2024 ´ëÇÑ»ê°ú¸¶ÃëÇÐȸ Á¦27Â÷ Çмú´ëȸ : 2024-06-15 0 4 2024-05-27
20804 ÃæºÏ 204 ÃæûºÏµµÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-06-15 0 8 2024-05-27
20803 ºÎ»ê 2024³â Á¦7ȸ ´ëÇÑÁßȯÀÚÀçÈ°ÇÐȸ Áý´ãȸ : 2024-06-15 0 3 2024-05-27
20802 ºÎ»ê 2024³â ´ëÇÑÁßȯÀÚÀçÈ°ÇÐȸ ¿öÅ©¼¥-±â´ÉÀû Æò°¡ ¹× ÁßȯÀÚ ÀçÈ°ÀÇ ½ÇÁ¦ (¿Ü»ó ÁßȯÀÚ Æ÷ÇÔ) : 2024-06-15 0 6 2024-05-27
20801 ¼­¿ï KLASS 20Áֳ⠱â³ä 2024 ´ëÇѺ¹°­°æÀ§Àå°ü¿¬±¸È¸ Á¦27ȸ Á¤±âÇмú´ëȸ : 2024-06-15 0 3 2024-05-27
20800 °æ±â 2024³â Á¦ 3ȸ Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-15 0 6 2024-05-27
20799 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ ÀÓ»óÁø·áÁöħ Æò°¡À§¿ø ¾ç¼º±³À° : 2024-06-15 0 1 2024-05-27
20798 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾÆû¼Ò³â°ú ºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2024-06-15 0 1 2024-05-27
20797 ¼­¿ï ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ COPD School 2024 : 2024-06-15 0 1 2024-05-27
20796 ¼­¿ï »óóÀå·ç¿¬±¸È¸ Áý´ãȸ : 2024-06-15 0 2 2024-05-27
20795 Àü³² 2024³â Àü¶ó³²µµÀÇ»çȸ Àü¹Ý±â Çмú´ëȸ : 2024-06-15 0 3 2024-05-27
20794 ¼­¿ï Ç÷°ü¿µ»ó»ý¸®¿¬±¸È¸ IPOP(Imaging and Physiology on Patients with Cardiovascular Disease) 2024 : 2024-06-15 0 1 2024-05-27
20793 ¼­¿ï ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ ¾à¹°¾Ë·¹¸£±â ½ÉÆ÷Áö¾ö : 2024-06-15 0 3 2024-05-27
20792 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀü, ÃæûÁöȸ - Á¦3Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-15 0 1 2024-05-27
20791 ¼­¿ï Á¦51ȸ ´ëÇÑÀÓ»óÇǺÎÄ¡·á¿¬±¸È¸ ±³À°½ÉÆ÷Áö¾ö : 2024-06-15 0 5 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷